{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:12:48Z","timestamp":1784941968847,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ORNATE India research grant GCRF UKRI"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1038\/s41433-022-02095-2","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T18:02:47Z","timestamp":1653674567000},"page":"2078-2083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Royal College of Ophthalmologists Commissioning guidelines on age macular degeneration: executive summary"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2634-9775","authenticated-orcid":false,"given":"Shruti","family":"Chandra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-243X","authenticated-orcid":false,"given":"Martin","family":"McKibbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-0659","authenticated-orcid":false,"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"AMD Commissioning Guidance Development Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Boparai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Broom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Crosby-Nwaobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenny","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Mankowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"McKibbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Yelf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"2095_CR1","unstructured":"National Institute for Health and Care Excellence. Age-related macular degeneration NICE guideline [NG82]. 2018."},{"key":"2095_CR2","unstructured":"National Institute for Health and Care Excellence. Serious eye disorders. 2019."},{"key":"2095_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1442-9071.2006.01135.x","volume":"34","author":"B Hussain","year":"2006","unstructured":"Hussain B, Saleh GM, Sivaprasad S, Hammond CJ. Changing from Snellen to logMAR: debate or delay?. Clin Exp Ophthalmol. 2006;34:6\u20138.","journal-title":"Clin Exp Ophthalmol"},{"key":"2095_CR4","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1097\/IAE.0000000000002220","volume":"39","author":"V Gualino","year":"2019","unstructured":"Gualino V, Tadayoni R, Cohen SY, Erginay A, Fajnkuchen F, Haouchine B, et al. Optical coherence tomography, fluorescein angiography, and diagnosis of choroidal neovascularization in age-related macular degeneration. Retin. 2019;39:1664\u201371.","journal-title":"Retin"},{"key":"2095_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41433-018-0229-6","volume":"33","author":"R Perrott-Reynolds","year":"2019","unstructured":"Perrott-Reynolds R, Cann R, Cronbach N, Neo YN, Ho V, McNally O. et al. The diagnostic accuracy of OCT angiography in naive and treated neovascular age-related macular degeneration: a review. Eye (Lond). 2019;33:274\u201382.","journal-title":"Eye (Lond)"},{"key":"2095_CR6","doi-asserted-by":"publisher","first-page":"7521478","DOI":"10.1155\/2016\/7521478","volume":"2016","author":"J Gong","year":"2016","unstructured":"Gong J, Yu S, Gong Y, Wang F, Sun X. The diagnostic accuracy of optical coherence tomography angiography for neovascular age-related macular degeneration: a comparison with fundus fluorescein angiography. J Ophthalmol. 2016;2016:7521478","journal-title":"J Ophthalmol"},{"key":"2095_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ajo.2016.06.042","volume":"169","author":"A Carnevali","year":"2016","unstructured":"Carnevali A, Cicinelli MV, Capuano V, Corvi F, Mazzaferro A, Querques L, et al. Optical coherence tomography angiography: a useful tool for diagnosis of treatment-naive quiescent choroidal neovascularization. Am J Ophthalmol. 2016;169:189\u201398.","journal-title":"Am J Ophthalmol"},{"key":"2095_CR8","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/bjophthalmol-2015-308077","volume":"100","author":"KC Madhusudhana","year":"2016","unstructured":"Madhusudhana KC, Lee AY, Keane PA, Chakravarthy U, Johnston RL, Egan CA, et al. UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections. Br J Ophthalmol. 2016;100:1617\u201322.","journal-title":"Br J Ophthalmol"},{"key":"2095_CR9","doi-asserted-by":"crossref","unstructured":"Ward E, Wickens RA, O\u2019Connell A, Culliford LA, Rogers CA, Gidman EA, et al. Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study. Eye. 2021;35:592\u2013600.","DOI":"10.1038\/s41433-020-0910-4"},{"key":"2095_CR10","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","volume":"36","author":"LN Kim","year":"2016","unstructured":"Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36:1418\u201331.","journal-title":"Retina"},{"key":"2095_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00417-019-04474-0","volume":"258","author":"JH Kim","year":"2020","unstructured":"Kim JH, Kim CG, Lee DW, Yoo SJ, Lew YJ, Cho HJ. et al. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2020;258:107\u201316.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2095_CR12","doi-asserted-by":"crossref","unstructured":"Maggio E, Deiro AP, Mete M, Sartore M, Polito A, Prigione G, et al. Intravitreal recombinant tissue plasminogen activator and sulphur hexafluoride gas for submacular hemorrhage displacement in age-related macular degeneration: looking behind the blood. Ophthalmologica. 2020;243:224\u201335.","DOI":"10.1159\/000505752"},{"key":"2095_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10384-019-00679-2","volume":"63","author":"S Kimura","year":"2019","unstructured":"Kimura S, Morizane Y, Hosokawa MM, Shiode Y, Doi S, Hosogi M. et al. Outcomes of vitrectomy combined with subretinal tissue plasminogen activator injection for submacular hemorrhage associated with polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2019;63:382\u20138.","journal-title":"Jpn J Ophthalmol"},{"key":"2095_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-015-0010-y","volume":"1","author":"R Merani","year":"2015","unstructured":"Merani R, Hunyor AP. Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. Int J Retin Vitreous. 2015;1:9.","journal-title":"Int J Retin Vitreous"},{"key":"2095_CR15","doi-asserted-by":"publisher","first-page":"1225.e1","DOI":"10.1016\/j.ophtha.2009.02.031","volume":"116","author":"KS Klein","year":"2009","unstructured":"Klein KS, Walsh MK, Hassan TS, Halperin LS, Castellarin AA, Roth D. et al. Endophthalmitis after anti-VEGF injections. Ophthalmology. 2009;116:1225.e1","journal-title":"Ophthalmology"},{"key":"2095_CR16","first-page":"361","volume":"19","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am. 2006;19:361\u201372.","journal-title":"Ophthalmol Clin North Am"},{"key":"2095_CR17","unstructured":"The Royal College of Ophthalmologists. Intravitreal Injection Therapy. 2018. https:\/\/curriculum.rcophth.ac.uk\/wp-content\/uploads\/2018\/02\/Intravitreal-Injection-Therapy-August-2018-2.pdf."},{"key":"2095_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/eye.2016.109","volume":"30","author":"P Hahn","year":"2016","unstructured":"Hahn P, Jiramongkolchai K, Stinnett S, Daluvoy M, Kim T. Rate of intraoperative complications during cataract surgery following intravitreal injections. Eye (Lond). 2016;30:1101\u20139.","journal-title":"Eye (Lond)"},{"key":"2095_CR19","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.ophtha.2016.02.014","volume":"123","author":"AY Lee","year":"2016","unstructured":"Lee AY, Day AC, Egan C, Bailey C, Johnston RL, Tsaloumas MD. et al. Previous intravitreal therapy is associated with increased risk of posterior capsule rupture during cataract surgery. Ophthalmology. 2016;123:1252\u20136.","journal-title":"Ophthalmology"},{"key":"2095_CR20","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2147\/OPTH.S232548","volume":"13","author":"JB Wingard","year":"2019","unstructured":"Wingard JB, Delzell DA, Houlihan NV, Lin J, Gieser JP. Incidence of glaucoma or ocular hypertension after repeated anti-vascular endothelial growth factor injections for macular degeneration. Clin Ophthalmol. 2019;13:2563\u201372.","journal-title":"Clin Ophthalmol"},{"key":"2095_CR21","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.ophtha.2021.07.025","volume":"128","author":"S Sivaprasad","year":"2021","unstructured":"Sivaprasad S, Banister K, Azuro-Blanco A, Goulao B, Cook JA, Hogg R. et al. Diagnostic accuracy of monitoring tests of fellow eyes in patients with unilateral neovascular age-related macular degeneration: early detection of neovascular age-related macular degeneration study. Ophthalmology. 2021;128:1736\u201347.","journal-title":"Ophthalmology"},{"key":"2095_CR22","unstructured":"Esme\u2019s Umbrella: Charles Bonnet Syndrome. 2020. https:\/\/www.charlesbonnetsyndrome.uk\/. Accessed 28 April 2020."},{"key":"2095_CR23","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1016\/j.ophtha.2012.05.047","volume":"119","author":"EM Stone","year":"2012","unstructured":"Stone EM, Aldave AJ, Drack AV, Maccumber MW, Sheffield VC, Traboulsi E. et al. Recommendations for genetic testing of inherited eye diseases: report of the American Academy of Ophthalmology task force on genetic testing. Ophthalmology. 2012;119:2408\u201310.","journal-title":"Ophthalmology"},{"key":"2095_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamaophthalmol.2015.0369","volume":"133","author":"EM Stone","year":"2015","unstructured":"Stone EM. Genetic testing for age-related macular degeneration: not indicated now. JAMA Ophthalmol. 2015;133:598\u2013600.","journal-title":"JAMA Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02095-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02095-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02095-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T08:07:28Z","timestamp":1666166848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02095-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2095"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-02095-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"assertion":[{"value":"11 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following interests have been declared by the group: SS has received funding from Boehringer Ingelheim, Novartis, Bayer, Allergan, Roche, Opthea, Optos, Oculis, Oxurion and Apellis for consultancy, research and speaking at symposia. PB has attended Roche Diabetic Eye Disease and neovascular AMD advisory board meetings. LD has been the Principal Investigator for sponsored clinical trials with Bayer, Novartis, Allergan, Roche and Alimera. She has also received fees for speaking at meetings from Bayer and Novartis and sponsorship for attending a meeting from Novartis, Bayer, and Allergan. ZR: the Local Optical Committee Support Unit provides advice on services to primary care providers and commissioners. CY: the Macular Society has received grants from the following companies: Alcon, Allergan (AbbVie), Apellis, Bayer, Novartis, OKKO health, Oxsight, Roche, Vision Express. It has also received consultancy fees from Novartis and an honorarium for her attendance at meetings of the Roche global Retina Patient Forum. SM has been the Principal Investigator for sponsored clinical trials with Bayer, Novartis and Roche. He has also received fees for advisory boards, lecturing and travel grants for meetings from Bayer and Novartis. RC-N has received an honorarium from Bayer for attending a Bayer Ophthalmology Masterclass event. None from other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}